arrow
C

Christian Chabannon

institut paoli-calmettes
H指数:61
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

出版商更正:定义造血移植和细胞治疗领域的全球优先事项:EBMT全球委员会的一份声明文件

2026-10-120
OAAI
Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article

去中心化CAR-T生产:临床、经济和监管视角。世界血液与骨髓移植网络(WBMT)专题文章

2026-09-240
PRE
Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee

定义全球造血移植和细胞治疗的优先事项:EBMT全球委员会声明文件

2026-08-110
OAAI
Update of the decision-making algorithm on selecting transfusion-dependent β-thalassemic patients for gene therapy approaches: joint consensus report on behalf of EHA-specialized working group and EBMT hemoglobinopathies working party

关于为输血依赖型β-地中海贫血患者选择基因治疗方案的决策算法更新:欧洲血液学协会专业工作组与欧洲血液和骨髓移植协会血红蛋白病工作组联合共识报告

2026-07-160
PRE
Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders

不同个体HLA在错配无关供者allo-HCT治疗恶性血液病中的进化分歧

2026-01-010
OA
Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link

确保学术生物生产UNITC网络中的原材料、试剂和消耗品供应:因为链条的强度取决于其最薄弱的环节。

2025-12-110
OAAI
Operational burden and fragmented implementation in CAR T-cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee

CAR T细胞治疗的运营负担与碎片化实施:来自GoCART联盟和JACIE质量经理委员会的多国调查的见解

2025-10-270
OAAI
Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation

更正:在资源有限国家中,使用非冷冻保存的自体外周血干细胞移植治疗多发性骨髓瘤和淋巴瘤:来自世界骨髓移植联盟的实践考量

2025-06-300
PRE
Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium

更正:学术生产CAR-T细胞质量控制测试的协调:UNITC联盟WP-bioproduction工作组立场文件

2025-06-300
OAAI
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation

建立嵌合抗原受体T细胞疗法项目:世界造血与骨髓移植网络交付框架

2025-05-230
PRE
CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party

CAR-T细胞生产失败和不符合规格的产品在真实世界环境中的情况:EBMT细胞治疗和免疫生物学工作组的一项调查

2025-05-150
PRE
The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party

欧洲间充质干细胞在糖皮质激素难治性急性移植物抗宿主病中的应用:欧洲血液和骨髓移植组细胞治疗与免疫生物学工作组调查

2025-02-200
PRE
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT

CAR-T细胞治疗中的免疫监测格局:EBMT细胞治疗与免疫生物学工作组撰写的综合综述和调查研究

2025-02-010
OAAI
Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)
2024-07-015
OAAI
Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
2024-04-027
OAAI